natgillin/translations-raw huggingface dataset:
Nycomed GmbH Byk-Gulden-Str.2 78467 Constance Germany
Madžarska Nycomed GmbH Byk-Gulden-Str.2 78467 Constance Nemčija
Zurcal 20 mg -Filmtabletten 20 mg Gastro-resistant tablet
Pantoprazol 20 mg Byk 20 mg gastrorezistentna tableta peroralna uporaba
Zurcal 40 mg -Filmtabletten 40 mg Gastro-resistant tablet
Ulcotenal 40 mg Blister 40 mg gastrorezistentna tableta peroralna uporaba
ANNEX CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES
DODATEK POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA, KI JIH MORAJO UVESTI DRŽAVE ČLANICE
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE ADDRESSED BY THE MEMBER STATES The Member States should ensure that the MAH provides an educational programme for Remicade to ensure that physicians who intend to prescribe Remicade to paediatric Crohn's disease patients are aware of:
POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA, KI JIH MORAJO OBRAVNAVATI DRŽAVE ČLANICE Države članice morajo zagotoviti, da bo imetnik dovoljenja za promet z zdravilom pripravil izobraževalni program o zdravilu Remicade, s katerim bi zagotovili, da se bodo zdravniki, ki želijo predpisovati zdravilo Remicade pediatričnim bolnikom s Crohnovo boleznijo, dobro zavedali naslednjih stvari:
• The risk of opportunistic infections and tuberculosis (TB) in patients treated with Remicade.
• tveganja za pojav oportunističnih okužb in tuberkuloze (TB) pri bolnikih, zdravljenih z zdravilom Remicade,
• The risk of lymphoma and other malignancies.
• tveganja za nastanek limfoma in drugih malignih bolezni,
• The risk of acute infusion related reactions and delayed hypersensitivity reactions.
• tveganja za pojav akutne infuzijske reakcije in poznih preobčutljivostnih reakcij,
• The need to assess the risk of TB in patients prior to treating with Remicade.
• potrebe po oceni tveganja za obstoj TB pri bolnikih še pred zdravljenjem z zdravilom Remicade,
• The patient alert card, which is to be given to patients using Remicade.
• da obstaja opozorilna kartica za bolnike, ki jo morajo dati vsem bolnikom, ki prejemajo zdravilo Remicade,
• That children may be at increased risk of developing infections and the need for immunisations to be up to date.
• da se lahko pri otrocih poveča tveganje za okužbe in je treba zato pri njih opraviti vsa cepljenja v skladu s programom.
Children and adolescents Use in children and adolescents under 18 years is not recommended.
Otroci in mladostniki Uporabe zdravila pri otrocih in mladostnikih mlajših od 18 let ne priporočamo.
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Pred začetkom jemanja zdravilo natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
It is recommended that you carry some sugar lumps, sweets, biscuits or sugary fruit juice.
Priporočljivo je, da imat pri sebi nekaj kock sladkorja, bonbone, piškote ali sladek sadni sok.
Your doctor will check whether Pioglitazone Teva Pharma is working 3 to 6 months after you start taking it.
Zdravnik bo preveril, ali zdravilo Pioglitazone Teva Pharma deluje, 3 do 6 mesecev po tem, ko začnete jemati zdravilo.
When treating patients who have at least one risk factor for development of congestive heart failure (e.g.
Pri zdravljenju bolnikov, ki imajo vsaj en dejavnik tveganja za razvoj kongestivnega srčnega popuščanja
Your blood sugar will be checked, and your dose of Pioglitazone Teva Pharma may need to be changed.
Preverili bodo raven vašega krvnega sladkorja in vaš odmerek zdravila Pioglitazon Teva Pharma bo morda potrebno spremeniti.
Date of latest renewal: 17 February 2017
Datum pridobitve dovoljenja za promet: 26. marec 2012 Datum zadnjega podaljšanja: 17. februar 2017
Do not use this medicine after the expiry date which is stated on the carton and the blister after “EXP”.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in na pretisnem omotu, poleg oznake EXP.
Pioglitazone Teva Pharma helps control the level of sugar in your blood when you have type 2 diabetes by helping your body make better use of the insulin it produces.
Zdravilo Pioglitazon Teva Pharma pomaga nadzorovati raven sladkorja v krvi, če imate sladkorno bolezen tipa 2, in sicer tako, da telesu pomaga bolje izkoristiti insulin, ki ga izdela.
If you take more Pioglitazone Teva Pharma than you should If you accidentally take too many tablets, or if someone else or a child takes your medicine, talk to a doctor or pharmacist immediately.
Če ste vzeli večji odmerek zdravila Pioglitazon Teva Pharma, kot bi smeli Če po nesreči zaužijete preveč tablet ali če kdo drug ali otrok zaužije vaša zdravila, nemudoma obvestite svojega zdravnika ali farmacevta.
When Pioglitazone Teva Pharma is taken in combination with other medicines used to treat diabetes (such as insulin, chlorpropamide, glibenclamide, gliclazide, tolbutamide) your doctor will tell you whether you need to take a smaller dose of your medicines.
Če boste jemali zdravilo Pioglitazon Teva Pharma skupaj z drugimi zdravili za zdravljenje sladkorne bolezni (kot so insulin, klorpropamid, glibenklamid, gliklazid, tolbutamid), vam bo zdravnik povedal, ali morate jemati nižje odmerke teh zdravil.
prior myocardial infarction or symptomatic coronary artery disease or the elderly), physicians should start with the lowest available dose and increase the dose gradually.
(npr. predhodni miokardni infarkt ali simptomatska koronarna arterijska bolezen), bi moral zdravnik začeti zdravljenje z najnižjim možnim odmerkom in ga postopoma višati.
If you take Pioglitazone Teva Pharma with other medicines for diabetes, it is more likely that your blood sugar could fall below the normal level (hypoglycaemia).
Če ste vzeli zdravilo Pioglitazon Teva Pharma z drugimi zdravili za zdravljenje sladkorne bolezni, je bolj verjetno, da vrednost vašega krvnega sladkorja pade pod normalno raven (hipoglikemija).
If you have the impression that the effect of Pioglitazone Teva Pharma is too weak, talk to your doctor.
Če menite, da je učinek zdravila Pioglitazon Teva Pharma prešibak, se posvetujte z zdravnikom.
50 x 1 tablets in Aluminium/aluminium perforated unit dose blisters.
50 x 1 tableta v aluminij/aluminij perforiranem pretisnem omotu za enkratni odmerek.
Other medicines and Pioglitazone Teva Pharma Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Druga zdravila in zdravilo Piaglitazon Teva Pharma Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali, ali pa boste morda začeli jemati katero koli drugo zdravilo.
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin.
Študije medsebojnih delovanj so pokazale, da pioglitazon nima pomembnega učinka na farmakokinetiko ali farmakodinamiko digoksina, varfarina, fenprokumona in metoformina.
2 Visual disturbance has been reported mainly early in treatment and is related to changes in blood glucose due to temporary alteration in the turgidity and refractive index of the lens as seen with other hypoglycaemic treatments.
2O motnjah vida so poročali predvsem zgodaj v poteku zdravljenja, povezane pa so s spremembami vrednosti glukoze v krvi zaradi začasnih sprememb turgidnosti in refrakcijskega indeksa leče, kot jih opažamo tudi pri zdravljenju z drugimi hipoglikemiki.
as monotherapy - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance
kot monoterapija - pri odraslih bolnikih (predvsem bolnikih s prekomerno telesno maso) nezadostno nadzorovanih z dieto in gibanjem, pri katerih je metformin, zaradi kontraindikacij ali neprenašanja, neprimeren.
Before you start taking Pioglitazone Teva Pharma you will have a blood sample taken to check your liver function.
Pred začetkom jemanja zdravila Pioglitazon Teva Pharma vam bodo odvzeli vzorec krvi, da se preveri delovanje vaših jeter.
You can usually continue to take other medicines whilst you are being treated with Pioglitazone Teva Pharma.
Običajno lahko še naprej jemljete druga zdravila medtem ko se zdravite z zdravilom Pioglitazon Teva Pharma.
It is an anti-diabetic medicine used to treat type 2 (non-insulin dependent) diabetes mellitus in adults, when metformin is not suitable or has failed to work adequately.
Je antidiabetično zdravilo za zdravljenje sladkorne bolezni tipa 2 (od insulina neodvisne sladkorne bolezni) pri odraslih, ko metformin ni primeren ali ne deluje na ustrezen način.
Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with Pioglitazone Teva Pharma and insulin experienced the development of heart failure.
Nekateri bolniki z dolgotrajno sladkorno boleznijo tipa 2 in srčno boleznijo ali predhodno kapjo, ki so bili zdravljeni z zdravilom Pioglitazon Teva Pharma in insulinom so doživeli razvoj srčnega popuščanja.
There may be an increased possibility of becoming pregnant because you may ovulate again when you take Pioglitazone Teva Pharma.
Obstaja povečana možnost zanositve, ker lahko spet pride do ovulacije, ko ste vzeli zdravilo Pioglitazon Teva Pharma.
Pioglitazone Teva Pharma with food and drink You may take your tablets with or without food.
Zdravilo Pioglitazon Teva Pharma skupaj s hrano in pijačo Tablete lahko zaužijete s hrano ali brez nje.
This medicine will not affect your ability to drive or use machines but take care if you experience abnormal vision.
Vpliv na sposobnost upravljanja vozil in strojev To zdravilo ne bo vplivalo na vašo sposobnost vožnje ali upravljanja strojev, vendar bodite pozorni če imate motnje vida.
- The other ingredients are mannitol, carmellose calcium, hydroxypropylcellulose and magnesium stearate.
- Druge pomožne snovi so manitol, hidroksipropilceluloza, kalcijev karmelozat in magnezijev stearat.
In this study in patients receiving pioglitazone and insulin, a higher percentage of patients with heart failure was observed in patients aged >65 years compared with those less than 65 years (9.7% compared to 4.0%).
V tej študiji so pri bolnikih, ki so se zdravili s pioglitazonom in z insulinom, večji odstotek srčnega popuščanja opazili pri bolnikih, starih 65 let in starejših, v primerjavi z bolniki, mlajšimi od 65 let (9,7 % v primerjavi s 4,0 %).
Pioglitazone undergoes extensive hepatic metabolism by hydroxylation of aliphatic methylene groups.
Biotransformacija Pioglitazon je podvržen obsežni jetrni presnovi s hidroksilacijo alifatskih metilenskih skupin.
Pioglitazone Teva Pharma has no or negligible influence on the ability to drive and use machines.
4.7 Vpliv na sposobnost vožnje in upravljanja strojev Zdravilo Pioglitazon Teva Pharma nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
What Pioglitazone Teva Pharma is and what it is used for What you need to know before you take Pioglitazone Teva Pharma How to take Pioglitazone Teva Pharma Possible side effects
Kaj je zdravilo Pioglitazon Teva Pharma in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Pioglitazon Teva Pharma Kako jemati zdravilo Pioglitazon Teva Pharma
The formation and presence of urinary calculi with subsequent irritation and hyperplasia was postulated as the mechanistic basis for the observed tumourigenic response in the male rat.
Domnevali so, da je nastajanje in prisotnost kamnov v sečilih s poznejšim draženjem in hiperplazijo, predstavljalo mehansko osnovo opaženega tumorogenega odgovora pri samcih podgan.
Merckle GmbH Ludwig-Merckle Strasse 3 89143 Blaubeuren Germany
Merckle GmbH Ludwig-Merckle Strasse 3
Pioglitazone Teva Pharma may also be used in patients who are unable to take metformin, and where treatment with diet and exercise has failed to control blood sugar or may be added to insulin therapy when it fails to provide sufficient control of blood sugar.
Zdravilo Pioglitazon Teva Pharma uporabljamo samo pri bolnikih, ki ne morejo jemati metformina, in ko zdravljenje z dieto in telesno vadbo ni uspešno pri nadzoru krvnega sladkorja.
This leaflet was last revised in {MM/YYYY}.
Navodilo je bilo nazadnje revidirano dne mesec/LLLL
Neoplasms benign, malignant and unspecified (including cysts and polyps) bladder cancer uncommon uncommon uncommon uncommon uncommon
Benigne, maligne in neopredelje ne novotvorbe (vključno s cistami in polipi) rak sečnega mehurja občasni občasni občasni občasni občasni
Similar changes were seen in metformin (haemoglobin 3-4% and haematocrit 3.6-4.1% relative reductions) and to a lesser extent sulphonylurea and insulin (haemoglobin 1-2% and haematocrit 1-3.2% relative reductions) treated patients in comparative controlled trials with pioglitazone.
zdravljenih z metforminom (hemoglobin 3-4 % in hematokrit 3,6-4,1 % relativna znižanja), in v manjšem obsegu pri bolnikih, zdravljenih s sulfonilsečnino in insulinom (hemoglobin 1-2 % in hematokrit 1-3,2 % relativna znižanja).
Reproductive system and breast disorders erectile dysfunction common
Motnje reproduk cije in dojk erektilna disfunkcija pogosti
In patients on insulin with no pioglitazone the incidence of heart failure was 8.2% in those >65 years compared to 4.0% in patients less than 65 years.
Pri bolnikih, ki so se zdravili samo z insulinom, brez pioglitazona, je odstotek srčnega popuščanja pri bolnikih, starih 65 let in starejših, znašal 8,2 %, pri bolnikih, mlajših od 65 let, pa 4,0 %.
How to store Pioglitazone Teva Pharma Contents of the pack and other information
Shranjevanje zdravila Pioglitazon Teva Pharma Vsebina pakiranja in dodatne informacije
If you are following a special diet for diabetes, you should continue with this while you are taking Pioglitazone Teva Pharma.
Če ste na posebni dieti za sladkorno bolezen, jo med jemanjem zdravila Pioglitazon Teva Pharma nadaljujte.
Combination with metformin with sulphonylurea with metformin and sulphonylurea with insulin
Kombinacija z metforminom s sulfonilsečnino z metfor minom in sulfonilsečnino z inzulinom
4 A pooled analysis was conducted of adverse reactions of bone fractures from randomised, comparator controlled, double blind clinical trials in over 8100 patients in the pioglitazone-treated groups and 7400 in the comparator-treated groups of up to 3.5 years duration.
4 Opravljena je bila skupna analiza neželenih učinkov zlomov kosti iz randomiziranih, s primerjalnim zdravilom nadzorovanih, dvojno slepih kliničnih preskušanj pri več kot 8100 bolnikov v skupini zdravljeni s pioglitazonom in 7400 v skupini zdravljeni s primerjalnim zdravilom, ki so trajale do
MARKETING AUTHORISATION HOLDER Teva B.V.
IMETNIK DOVOLJENJA ZA PROMET Teva B.V.
Bladder cancer has been experienced uncommonly (may affect up to 1 in 100 people) in patients taking pioglitazone.
Rak mehurja se lahko pojavi občasno (pojavijo se lahko pri največ 1 od 100 bolnikov) pri bolnikih, ki jemljejo pioglitazon.
If you stop taking Pioglitazone Teva Pharma
Če ste prenehali jemati zdravilo Pioglitazon Teva Pharma
14 tablets 28 tablets 30 tablets 50 tablets 56 tablets 84 tablets 90 tablets 98 tablets 112 tablets 196 tablets 50 x 1 tablets
14 tablet 28 tablet 30 tablet 50 tablet 56 tablet 84 tablet 90 tablet 98 tablet 112 tablet 196 tablet 50 x 1 tablet
Infections and infestations upper respiratory tract infection common common common common common bronchitis common sinusitis uncommon uncommon uncommon uncommon uncommon
Infekcijske in parazitske bolezni okužba zgornjih dihal pogosti pogosti pogosti pogosti pogosti bronhitis pogosti sinusitis občasni občasni občasni občasni občasni
Do not take Pioglitazone Teva Pharma - if you are allergic to pioglitazone or any of the other ingredients of this medicine (listed in section 6).
- če ste preobčutljivi na pioglitazon ali katero koli sestavino tega zdravila (navedeno v poglavju
common common common common common blood creatine phospho-kinase increased common increased lactic dehydro-genase uncommon alanine aminotransferase increased7
pogosti pogosti pogosti pogosti pogosti povišana vrednost keratin fosfokinaze v krvi pogosti povišana vrednost laktatne dehidrogenaze občasni povišana vrednost alanin aminotransferaze7
common common uncommon macular oedema not known not known not known not known not known Ear and labyrinth disorders vertigo uncommon
pogosti pogosti občasni makularni edem neznana neznana neznana neznana neznana
Your doctor will ask you to have blood tests periodically during treatment with Pioglitazone Teva Pharma.
Zdravnik vas bo v času zdravljenja z zdravilom Pioglitazon Teva Pharma naročil na redne preiskave krvi.
prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained (see section 4.4).
Glede na možna tveganja pri dolgotrajni terapiji, mora zdravnik potrditi pri rednih rutinskih pregledih, da je korist pioglitazona ohranjena (glejte poglavje 4.4).
‘15' on one side and ‘TEVA' on the other side.
izbočene, z oznako »45« na eni strani in »TEVA« na drugi strani.
Concomitant administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) or with rifampicin (an inducer of cytochrome P450 2C8) is reported to increase or decrease, respectively, the plasma concentration of pioglitazone (see section 4.5).
Poročali so, da sočasno dajanje pioglitazona z gemfibrozilom (zaviralec citokroma P450 2C8) ali rifampicina (induktor citokroma P450 2C8) poviša oziroma zniža plazemsko koncentracijo pioglitazona (glejte poglavje 4.5).
- The tablets are supplied in Aluminium/aluminium blisters in packs of 14, 28, 30, 50, 56, 84, 90, 98, 112 or 196 tablets or 50 x 1 tablets in Aluminium/aluminium perforated unit dose blisters.
- Tablete so na voljo v aluminij/aluminij pretisnih omotih v pakiranjih po 14, 28, 30, 50, 56, 84, 90, 98, 112 ali 196 tablet ali kot 50 x 1 tableta v aluminij/aluminij perforiranem pretisnem omotu za enkratni odmerek.
DATE OF REVISION OF THE TEXT {MM/YYYY}
DATUM ZADNJE REVIZIJE BESEDILA
EU/1/12/758/032
EU/1/12/758/021-030 EU/1/12/758/032
Take Pioglitazone Teva Pharma daily as prescribed.
Če ste pozabili vzeti zdravilo Pioglitazon Teva Pharma Zdravilo Pioglitazon Teva Pharma jemljite vsak dan, kakor vam je predpisano.
Manufacturer:
Izdelovalci
4.4 Special warnings and precautions for use
4.4 Posebna opozorila in previdnostni ukrepi Zastajanje tekočine in srčno popuščanje
Pioglitazone Teva Pharma 15 mg tablets Aluminium/aluminium blisters, packs of 14, 28, 30, 50, 56, 84, 90, 98, 112 and 196 tablets
Pioglitazon Teva Pharma 15 mg tablete Aluminij/aluminij pretisni omoti, pakiranja po 14, 28, 30, 50, 56, 84, 90, 98, 112 in 196 tablet.
Pioglitazone Teva Pharma should be used every day to work properly.
Za pravilno delovanje je potrebno zdravilo Pioglitazon Teva Pharma jemanti vsak dan.
What you need to know before you take Pioglitazone Teva Pharma
Kaj morate vedeti, preden boste vzeli zdravilo Pioglitazon Teva Pharma Ne jemljite zdravila Pioglitazon Teva Pharma
Respiratory, thoracic and mediastinal disorders dyspnoea common
Bolezni dihal, prsnega koša in media stinalnega prostora dispneja pogosti
Immune System Disorders hypersensitivity and allergic reactions1
- povišanje vrednosti jetrnih encimov - alergijske reakcije
- Pioglitazone Teva Pharma 45 mg tablets are white to off white, round, convex with the number ‘45' on one side and ‘TEVA' on the other side.
- Tablete zdravila Pioglitazon Teva Pharma 15 mg so bele do umazano bele barve, okrogle, izbočene, z oznako »15« na eni strani in »TEVA« na drugi strani.
How to store Pioglitazone Teva Pharma
Shranjevanje zdravila Pioglitazon Teva Pharma
common (may affect up to 1 in 10 people) - headache - dizziness - joint pain - impotence - back pain - shortness of breath - small reduction in red blood cell count - flatulence uncommon (may affect up to 1 in 100 people) - sugar in urine, proteins in urine - increase in enzymes - spinning sensation (vertigo) sweating tiredness increased appetite
- vetrovi občasni (pojavijo se lahko pri največ 1 od 100 bolnikov) - sladkor v urinu, beljakovine v urinu - povišanje vrednosti encimov
No increase in fracture rates was observed in men treated with pioglitazone (1.7%) versus comparator (2.1%).
Pri moških, zdravljenih s pioglitazonom, niso opazili povečane stopnje zlomov (1,7 %) v primerjavi s primerjalnim zdravilom
In the 3.5 year cardiovascular risk PROactive study, 44/870 (5.1%; 1.0 fractures per 100 patient years) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%; 0.5 fractures per 100 patient years) of female patients treated with comparator.
100 bolniških let) žensk, zdravljenih s pioglitazonom imelo zlome, v primerjavi s 23/905 (2,5 %; 0,5 zlomov na 100 bolniških let) žensk, zdravljenih s primerjalnim zdravilom.
If you stop using Pioglitazone Teva Pharma, your blood sugar may go up.
Če ste prenehali jemati zdravilo Pioglitazon Teva Pharma, se vam lahko raven krvnega sladkorja zviša, zato se posvetujte z zdravnikom, preden prenehate s tem zdravljenjem.
Pioglitazone Teva Pharma 30 mg tablets Each tablet contains 30 mg of pioglitazone (as hydrochloride).
Pioglitazon Teva Pharma 30 mg tablete Ena tableta vsebuje 30 mg pioglitazona (v obliki pioglitazonijevega klorida).
The other side effects that have been experienced by some patients when pioglitazone is taken with other antidiabetic medicines are:
4.3 Kontraindikacije Pioglitazon je kontraindiciran pri bolnikih:
Pioglitazone Teva Pharma 45 mg tablets Each tablet contains 45 mg of pioglitazone (as hydrochloride).
Pioglitazon Teva Pharma 45 mg tablete Ena tableta vsebuje 45 mg pioglitazona (v obliki pioglitazonijevega klorida).
Pioglitazone Teva Pharma 15 mg tablets Each tablet contains 15 mg of pioglitazone (as hydrochloride).
Pioglitazon Teva Pharma 15 mg tablete Ena tableta vsebuje 15 mg pioglitazona (v obliki pioglitazonijevega klorida).
Pioglitazone is contraindicated in patients with: - hypersensitivity to the active substance or to any of the excipients listed in section 6.1 - cardiac failure or history of cardiac failure (NYHA stages I to IV) - hepatic impairment - diabetic ketoacidosis - current bladder cancer or a history of bladder cancer - uninvestigated macroscopic haematuria
- s preobčutljivostjo na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju - s srčnim popuščanjem ali srčnim popuščanjem v anamnezi (NYHA razredi od I do IV)
Each Pioglitazone Teva Pharma 30 mg tablet contains 30 mg of pioglitazone (as hydrochloride).
Ena 30-miligramska tableta Pioglitazon Teva Pharma vsebuje 30 mg pioglitazona (v obliki pioglitazonijevega klorida).
Combination with metformin with sulphonylurea with metformin and sulphonylurea with insulin dizziness common insomnia uncommon uncommon uncommon uncommon uncommon
Kombinacija z metforminom s sulfonilsečnino z metfor minom in sulfonilsečnino z inzulinom kože in podkožja znojenje občasni
very common (may affect more than 1 in 10 people) - decreased blood sugar (hypoglycaemia)
pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov) - glavobol - omotica - vetrovi
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET
What Pioglitazone Teva Pharma looks like and contents of the pack - Pioglitazone Teva Pharma 15 mg tablets are white to off white, round, convex with the number
- Tablete zdravila Pioglitazon Teva Pharma 30 mg so bele do umazano bele barve, okrogle,
- The tablets are supplied in Aluminium/aluminium blisters in packs of 14, 28, 30, 50, 56, 84, 90,
- Tablete so na voljo v aluminij/aluminij pretisnih omotih v pakiranjih po 14, 28, 30, 50, 56, 84, 90, 98, 112 ali 196 tablet.
Each Pioglitazone Teva Pharma 45 mg tablet contains 45 mg of pioglitazone (as hydrochloride).
Ena 45-miligramska tableta Pioglitazon Teva Pharma vsebuje 45 mg pioglitazona (v obliki pioglitazonijevega klorida).
MARKETING AUTHORISATION NUMBER(S) EU/1/12/758/011-020
EU/1/12/758/011-020 EU/1/12/758/031
Each Pioglitazone Teva Pharma 15 mg tablet contains 15 mg of pioglitazone (as hydrochloride).
Ena 15-miligramska tableta Pioglitazon Teva Pharma vsebuje 15 mg pioglitazona (v obliki pioglitazonijevega klorida).